⌘K
t
On March 11, 2025, Convatec Group Plc announced that its Annual General Meeting will be held on May 22, 2025, at 14:00 (UK time). The Annual Report and Accounts for the year ended December 31, 2024, and the Notice of Annual General Meeting, including a copy of the Convatec Group Omnibus Incentive Plan, have been sent to shareholders and submitted to the National Storage Mechanism. These documents are available on the company's website.
| Date | 11 Mar 2025 |
| Time | 09:00:01 |
| Category | Results |
| ID | 0839A |
11 March 2025
Convatec Group Plc
("Convatec" or "the Company")
Annual Report and Accounts 2024 and Notice of Annual General Meeting
The Company's annual general meeting (the "Annual General Meeting") will take place at 14:00 (UK time) on Thursday 22 May 2025 at FGS Global, The Adelphi, 1-11 John Adam Street, London WC2N 6HT.
The Company's Annual Report and Accounts for the year ended 31 December 2024 and the Notice of Annual General Meeting, including details of how shareholders can appoint a proxy, are being sent to shareholders today and have been submitted to the National Storage Mechanism in accordance with paragraph 17.2.1 of the FCA Listing Rules. A copy of the Convatec Group Omnibus Incentive Plan has also been submitted to the National Storage Mechanism. These documents will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
A copy of the Company's Annual Report and Accounts and the Notice of Annual General Meeting can be accessed on the Company's website at www.convatecgroup.com.
This announcement is made in accordance with DTR 6.3.5R(1A).
Enquiries
James Kerton, Company Secretary
Tel: +44 (7827) 036059
Email: cosec@convatec.com
Convatec Group Plc's LEI code is 213800LS272L4FIDOH92
Classification: 1.1 Annual financial and audit reports
About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide our products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Convatec's revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com